http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 19 Aug 2026 07:52:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+18/26947328.html si-local-file:///var/storage/secattach/20260819/26947328.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+18/26947328.html Wed, 19 Aug 2026 07:52:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+18/26947328.html si-local-file:///var/storage/secattach/20260819/26947328.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+18/26947328.html Wed, 19 Aug 2026 07:52:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+18/26947328.html si-local-file:///var/storage/secattach/20260819/26947328.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+18/26947328.html Wed, 19 Aug 2026 07:52:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/Downgrades/JPMorgan+Downgrades+Mereo+BipPharma+Group+%28MREO%29+to+Underweight/26944869.html <p>JPMorgan analyst Priyanka Grover downgraded Mereo BipPharma Group (NASDAQ: MREO) from Neutral to Underweight.</p><p>For an analyst ratings summary and ratings history on Mereo BipPharma Group <a href="http://www.streetinsider.com/rating_history.php?q=MREO">click here</a>. For more ratings news on Mereo BipPharma Group <a href="http://www.streetinsider.com/stock_lookup_news.php?q=MREO&amp;type=analyst">click here</a>.</p><p>Shares of Mereo BipPharma Group closed at $0.31 yesterday.</p> http://www.streetinsider.com/Downgrades/JPMorgan+Downgrades+Mereo+BipPharma+Group+%28MREO%29+to+Underweight/26944869.html Tue, 18 Aug 2026 16:35:33 -0400 MREO http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Mereo+BioPharma+Group++++++++++++++++++Filed+by%3A+EcoR1+Capital%2C+LLC/26928113.html si-local-file:///var/storage/secattach/20260814/26928113.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Mereo+BioPharma+Group++++++++++++++++++Filed+by%3A+EcoR1+Capital%2C+LLC/26928113.html Fri, 14 Aug 2026 12:57:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Mereo+BioPharma+Group++++++++++++++++++Filed+by%3A+EcoR1+Capital%2C+LLC/26928113.html si-local-file:///var/storage/secattach/20260814/26928113.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Mereo+BioPharma+Group++++++++++++++++++Filed+by%3A+EcoR1+Capital%2C+LLC/26928113.html Fri, 14 Aug 2026 12:57:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Mereo+BioPharma+Group++++++++++++++++++Filed+by%3A+EcoR1+Capital%2C+LLC/26928113.html si-local-file:///var/storage/secattach/20260814/26928113.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Mereo+BioPharma+Group++++++++++++++++++Filed+by%3A+EcoR1+Capital%2C+LLC/26928113.html Fri, 14 Aug 2026 12:57:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/Earnings/Mereo+BioPharma+%28MREO%29+Reports+In-Line+Q2+EPS/26902962.html <p>Mereo BioPharma (NASDAQ: MREO) reported Q2 EPS of ($0.01), in-line with the analyst estimate of ($0.01).</p><p>For earnings history and earnings-related data on Mereo BioPharma (MREO) <a href="http://www.streetinsider.com/ec_earnings.php?q=MREO">click here</a>.</p> http://www.streetinsider.com/Earnings/Mereo+BioPharma+%28MREO%29+Reports+In-Line+Q2+EPS/26902962.html Tue, 11 Aug 2026 09:33:59 -0400 MREO http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Mereo+BioPharma+Group+++++For%3A+Jun+30/26902189.html si-local-file:///var/storage/secattach/20260811/26902189.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Mereo+BioPharma+Group+++++For%3A+Jun+30/26902189.html Tue, 11 Aug 2026 08:38:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Mereo+BioPharma+Group+++++For%3A+Jun+30/26902189.html si-local-file:///var/storage/secattach/20260811/26902189.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Mereo+BioPharma+Group+++++For%3A+Jun+30/26902189.html Tue, 11 Aug 2026 08:38:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Mereo+BioPharma+Group+++++For%3A+Jun+30/26902189.html si-local-file:///var/storage/secattach/20260811/26902189.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Mereo+BioPharma+Group+++++For%3A+Jun+30/26902189.html Tue, 11 Aug 2026 08:38:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+11/26902012.html si-local-file:///var/storage/secattach/20260811/26902012.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+11/26902012.html Tue, 11 Aug 2026 08:26:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+11/26902012.html si-local-file:///var/storage/secattach/20260811/26902012.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+11/26902012.html Tue, 11 Aug 2026 08:26:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+11/26902012.html si-local-file:///var/storage/secattach/20260811/26902012.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mereo+BioPharma+Group+++++For%3A+Aug+11/26902012.html Tue, 11 Aug 2026 08:26:00 -0400 0A9G MREO O.22553658 http://www.streetinsider.com/Corporate+News/Mereo+BioPharma+posts+Q2+loss%2C+signs+alvelestat+deal+with+Sentynl/26901980.html <p>Mereo BioPharma Group plc (NASDAQ: MREO) reported a net loss of $7.0 million for the second quarter ended June 30, 2026, compared with a net loss of $14.6 million in the same period a year earlier, according to a company press release.</p><p>The London-based clinical-stage biopharmaceutical company signed an option and license agreement with Sentynl Therapeutics, Inc., a wholly owned subsidiary of Zydus Lifesciences Limited, granting Sentynl the right to acquire U.S. commercial and global manufacturing rights to alvelestat, Mereo's investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease. If Sentynl exercises the option, Mereo would be eligible to receive $40 http://www.streetinsider.com/Corporate+News/Mereo+BioPharma+posts+Q2+loss%2C+signs+alvelestat+deal+with+Sentynl/26901980.html Tue, 11 Aug 2026 08:17:50 -0400 MREO http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html <p align="center"><em>Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)</em></p> <p align="center"><em>Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026</em></p> <p align="center"><em>Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027</em></p> <p>LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html Tue, 11 Aug 2026 08:15:00 -0400 A.06822034 A.14797296 A.50216919 MREO O.00097061 O.20026344 O.22076191 O.22553658 http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html <p align="center"><em>Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)</em></p> <p align="center"><em>Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026</em></p> <p align="center"><em>Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027</em></p> <p>LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html Tue, 11 Aug 2026 08:15:00 -0400 A.06822034 A.14797296 A.50216919 MREO O.00097061 O.20026344 O.22076191 O.22553658 http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html <p align="center"><em>Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)</em></p> <p align="center"><em>Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026</em></p> <p align="center"><em>Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027</em></p> <p>LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html Tue, 11 Aug 2026 08:15:00 -0400 A.06822034 A.14797296 A.50216919 MREO O.00097061 O.20026344 O.22076191 O.22553658 http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html <p align="center"><em>Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)</em></p> <p align="center"><em>Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026</em></p> <p align="center"><em>Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027</em></p> <p>LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html Tue, 11 Aug 2026 08:15:00 -0400 A.06822034 A.14797296 A.50216919 MREO O.00097061 O.20026344 O.22076191 O.22553658 http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html <p align="center"><em>Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)</em></p> <p align="center"><em>Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026</em></p> <p align="center"><em>Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027</em></p> <p>LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html Tue, 11 Aug 2026 08:15:00 -0400 A.06822034 A.14797296 A.50216919 MREO O.00097061 O.20026344 O.22076191 O.22553658 http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html <p align="center"><em>Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)</em></p> <p align="center"><em>Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026</em></p> <p align="center"><em>Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027</em></p> <p>LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html Tue, 11 Aug 2026 08:15:00 -0400 A.06822034 A.14797296 A.50216919 MREO O.00097061 O.20026344 O.22076191 O.22553658 http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html <p align="center"><em>Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)</em></p> <p align="center"><em>Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026</em></p> <p align="center"><em>Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027</em></p> <p>LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html Tue, 11 Aug 2026 08:15:00 -0400 A.06822034 A.14797296 A.50216919 MREO O.00097061 O.20026344 O.22076191 O.22553658 http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html <p align="center"><em>Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)</em></p> <p align="center"><em>Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026</em></p> <p align="center"><em>Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027</em></p> <p>LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial http://www.streetinsider.com/Press+Releases/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html Tue, 11 Aug 2026 08:15:00 -0400 A.06822034 A.14797296 A.50216919 MREO O.00097061 O.20026344 O.22076191 O.22553658 http://www.streetinsider.com/Globe+Newswire/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html <p align="center"><em>Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)</em></p> <p align="center"><em>Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026</em></p> <p align="center"><em>Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027</em></p> <p>LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial http://www.streetinsider.com/Globe+Newswire/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html Tue, 11 Aug 2026 08:15:00 -0400 A.06822034 A.14797296 A.50216919 MREO O.00097061 O.20026344 O.22076191 O.22553658 http://www.streetinsider.com/Globe+Newswire/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html <p align="center"><em>Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)</em></p> <p align="center"><em>Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026</em></p> <p align="center"><em>Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027</em></p> <p>LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial http://www.streetinsider.com/Globe+Newswire/Mereo+BioPharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Highlights/26901967.html Tue, 11 Aug 2026 08:15:00 -0400 A.06822034 A.14797296 A.50216919 MREO O.00097061 O.20026344 O.22076191 O.22553658